---
title: "management_refractory_recurrent_and_metastatic_disease_of_anal_cancer"
date: "2024-09-04"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[anal cancer]]

# management_refractory_recurrent_and_metastatic_disease_of_anal_cancer

- Confirm progression w/ bx & restaging CT or MRI, consider PET
- If locally progressive,
  - proceed to salvage [[apr.md|APR]]
- For unresectable or metastatic, 1st-line standard Rx includes carbo/paclitaxel (preferred), FOLFCIS, FOLFOX, 5-FU + cis, modified DCF. 2nd line includes nivolumab & pembrolizumab.
  - Modification to dose & schedule may be necessary
- No evidence exists to support metastasectomy in anal CA. Regional Rx in select pts w/ limited dz
- Clinical trial preferred
